Lv1
12 积分 2026-09-28 加入
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
3天前
已完结
Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
3天前
已完结
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
1个月前
已完结
An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer
1个月前
已完结